IVVD (Invivyd) Interest Coverage : No Debt ⁽¹⁾ (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Invivyd Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Invivyd's Operating Income for the three months ended in Dec. 2024 was $-19.23 Mil. Invivyd's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Invivyd has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Invivyd Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Invivyd's Interest Coverage or its related term are showing as below:

IVVD's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Invivyd Interest Coverage Historical Data

The historical data trend for Invivyd's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Invivyd Interest Coverage Chart

Invivyd Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

No Debt

N/A

No Debt

Invivyd Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Coverage	Get a 7-Day Free Trial													N/A	N/A	No Debt	N/A	No Debt

Competitive Comparison of Invivyd's Interest Coverage

For the Biotechnology subindustry, Invivyd's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invivyd's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invivyd's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Invivyd's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Invivyd Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Invivyd's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Invivyd's Interest Expense was $0.00 Mil. Its Operating Income was $-176.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Invivyd had no debt ⁽¹⁾.

Invivyd's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, Invivyd's Interest Expense was $0.00 Mil. Its Operating Income was $-19.23 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Invivyd had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Invivyd (NAS:IVVD) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Invivyd Interest Coverage Related Terms

Thank you for viewing the detailed overview of Invivyd's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Invivyd Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451

Website

https://www.invivyd.com

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Executives

Terrance Mcguire	director, other: See Remarks	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Adimab, Llc	10 percent owner, other: See Remarks	7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke	officer: Chief Financial Officer	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter	director	1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii	officer: Chief Scientific Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price	officer: Chief Tech. and Manuf. Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler	officer: COO & CCO	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora	officer: Chief Tech and Manuf Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt	officer: Chief Medical Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen	officer: Chief Legal Officer, Secretary	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom	director	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll	officer: Interim CFO
David Hering	director, officer: Chief Executive Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia	director, other: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp	other: See Remarks	700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902